Conference Home

 

Conference Home

Scientific Agenda & Faculty

Accommodations & Travel

Sponsorship


The 2016 Immuno-Oncology Update+

The 2016 Immuno-Oncology Update+ is a one and a half day event being held Friday, September 23rd to Saturday, September 24th, 2016 in downtown Toronto, Ontario. The Congress will be chaired by Dr. Sunil Verma (see below for biography).

This year's program will cover a variety of important topics examining advances in immuno-oncology and also explore topics that pertain to clinical practice, adverse event management and the pharmacoeconomics of novel therapies. Immuno-Oncology Update+ will draw from among experts in immuno-oncology from across North America. 

Please contact penelope@eocipharma.com with questions regarding this event.

Learning Objectives:

  • To review basic principles of immuno-oncology as well as key advances in different tumour sites
  • To discuss best practices and practical implications for patient management
  • To examine adverse event management of novel therapies
  • To discuss the pharmacoeconomics of these agents
To view session specific learning objectives, click here

FEES:

Early Bird Price, Ending September 1st, 2016

Nurses/Pharmacists/Residents/Allied Healthcare Providers: $89 CAD

Physicians: $159 CAD


Regular Price, After September 1st, 2016

Nurses/Pharmacists/Residents/Allied Healthcare Providers: $129 CAD

Physicians: $199 CAD

Industry Badge: $750 CAD


About the Chair:

Dr. Sunil Verma, MD, MSEd, FRCPC is a Professor at the University of Calgary and Medical Director at the Tom Baker Cancer Centre. He completed his internal medicine and medical oncology training at the University of Alberta and then went on to a fellowship in breast cancer at the University of Toronto. He also completed his Master of Science in medical education from the University of California during his fellowship years.

Dr. Verma’s main clinical interests are in the treatment and management of breast cancer and lung cancer. He also has key research interests in neoadjuvant and endocrine treatment of breast cancer, reducing toxicity of systemic treatment, and developing novel therapies in breast and lung cancer. He has won numerous teaching awards and has also been recognized with many awards for his mentorship.

Dr. Verma has led and created a number of national and international educational projects in oncology. He is well published, including being first author in New England Journal of Medicine along with other prestigious journals and is recognized internationally for his research and education leadership in breast and lung cancer. He is a member of several professional societies including ASCO, the Canadian Association of Medical Oncologists, and the Canadian Medical Association.